Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update
Lund, Sweden September 30, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English. Slides used in the presentation will be live on the company website during the call under “